Ventricular Assist System Applications in End-stage Heart Failure

Basit Öğe Kaydı
dc.contributor.authorYagdi, T.
dc.contributor.authorOguz, E.
dc.contributor.authorAyik, F.
dc.contributor.authorErtugay, S.
dc.contributor.authorNalbantgil, S.
dc.contributor.authorEngin, C.
dc.contributor.authorOzbaran, M.
dc.date.accessioned2019-10-27T21:24:32Z
dc.date.available2019-10-27T21:24:32Z
dc.date.issued2011
dc.departmentEge Üniversitesien_US
dc.description22nd Congress of the Spanish-Liver-Transplantation-Society (SETH) -- OCT 29-30, 2010 -- Madrid, SPAINen_US
dc.description.abstractBackground. Mechanical circulatory support has an important role in the surgical therapy for heart failure. Patients deteriorating on transplantation waiting lists or those unsuitable for transplantation have been treated with ventricular assist devices. In this report, we have presented application of ventricular assist systems for patients with end-stage heart failure. Methods. Between April 2007 and September 2010, we treated 37 patients with end-stage heart failure with mechanical circulatory support, including 5 children younger than 16 years of age. Three patients were females, and the overall mean age was 40 18 years (range, 1.5-67). In 29 patients we implanted paracorporeal pneumatic ventricular assist devices. Axial flow pumps were chosen to support the left ventricle in 8 patients. Biventricular support was applied in 9 patients because of their poor preoperative clinical conditions and advanced evidence of right ventricular failure. Results. Heart transplantation was performed in 16 patients (43%). One subject, who was managed with a left ventricular assist device implantation and coronary bypass grafting, was weaned from the system because of recovery of ventricular functions. Eleven patients (30%) are still on pump support. Nine patients (24%) died during mechanical circulatory support. The most prevalent cause of mortality was multiorgan failure (n = 5; 13.5%). Cerebrovascular hemorrhage was the cause of death in 2 patients. One patient died due to acute lung injury, and an other due to malignant melanoma. Conclusion. Use of a ventricular assist device as a bridge-to-transplantation or as destination therapy can be performed with acceptable mortality. It may be the most promising option for patients with end-stage heart failure. Development of device technology, advanced monitoring of anticoagulation and anti-aggregation therapy, and greater clinical experience may yield better results.en_US
dc.description.sponsorshipSpanish Liver Transplantation Socen_US
dc.identifier.doi10.1016/j.transproceed.2011.01.116en_US
dc.identifier.endpage926en_US
dc.identifier.issn0041-1345
dc.identifier.issue3en_US
dc.identifier.pmid21486629en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage923en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2011.01.116
dc.identifier.urihttps://hdl.handle.net/11454/44573
dc.identifier.volume43en_US
dc.identifier.wosWOS:000289860300059en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleVentricular Assist System Applications in End-stage Heart Failureen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu